Deal Details

Karyopharm Completes $165 Million Private Placement

Healthcare

Karyopharm private placement

Summary

Karyopharm Therapeutics Inc. (“Karyopharm”) (NASDAQ:KPTI) recently announced a private placement of 31,791,908 shares of common stock at a price of $5.19 per share and accompanying warrants to purchase 9,537,563 shares of common stock with an exercise price of $6.36 per share. Gross proceeds from the offering were approximately $165 million, before deducting any offering related expenses. The private placement was led by Avidity Partners, with participation by existing stockholders and new investors including Adage Capital Partners LP, Armistice Capital, Healthcor Management LP, Heights Capital Management, Marshall Wace, Rubric Capital Management LP, SilverArc Capital and Surveyor Capital (a Citadel company).

Baird acted as a co-placement agent on this offering.

About

Karyopharm is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm’s lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the United States and marketed by Karyopharm in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-United States territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis. Karyopharm Therapeutics Inc. is headquartered in Newton, Massachusetts.

Healthcare

Karyopharm private placement